Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Free Cash Flow (2016 - 2026)

Syndax Pharmaceuticals (SNDX) has disclosed Free Cash Flow for 12 consecutive years, with -$50.3 million as the latest value for Q1 2026.

  • For Q1 2026, Free Cash Flow rose 47.1% year-over-year to -$50.3 million; the TTM value through Mar 2026 reached -$278.2 million, up 2.9%, while the annual FY2025 figure was -$323.2 million, 17.56% down from the prior year.
  • Free Cash Flow hit -$50.3 million in Q1 2026 for Syndax Pharmaceuticals, up from -$69.5 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at -$22.9 million in Q4 2022 and bottomed at -$95.2 million in Q1 2025.
  • Average Free Cash Flow over 5 years is -$55.4 million, with a median of -$50.3 million recorded in 2026.
  • Year-over-year, Free Cash Flow plummeted 122.73% in 2022 and then skyrocketed 47.1% in 2026.
  • Syndax Pharmaceuticals' Free Cash Flow stood at -$22.9 million in 2022, then plummeted by 80.61% to -$41.3 million in 2023, then crashed by 38.79% to -$57.4 million in 2024, then decreased by 21.18% to -$69.5 million in 2025, then increased by 27.61% to -$50.3 million in 2026.
  • According to Business Quant data, Free Cash Flow over the past three periods came in at -$50.3 million, -$69.5 million, and -$70.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.